Cognizant (NASDAQ: CTSH ) today announced major advancements to its Cognizant Neuro ^® AI platform , which helps enterprises rapidly discover, prototype and develop AI use cases to improve decision-making, driving improved business performance and new revenue opportunities.

According to data from a survey by  Cognizant and Oxford Economics, most companies (76%) want to use AI to create new revenue streams, but struggle to implement and scale cross-enterprise use cases. Many (70%) also feel they’re not moving fast enough. The enhancements to Cognizant Neuro® ^AI  focus on addressing these issues. In just minutes, business leaders can identify business problems to address, scope them, and generate synthetic data or import their own anonymized data to build AI models. The platform can then make predictions and provide guidance on how to achieve business outcomes and justify those decisions, enabling companies to quickly assess the impact of a variety of use cases. 

The enhanced Cognizant Neuro® ^AI  platform is now available to Cognizant clients and has already been tested, piloted, and deployed by dozens of customers. The platform is backed by multiple patents and can be used in virtually any industry or business that relies on data analytics, ranging from inventory management and dynamic pricing to fraud reduction and efficient workforce allocation. The enhancements to the Neuro® ^AI  platform began as research projects in the Cognizant AI Research Lab, which launched earlier this year . The lab focuses on the study and development of decision-based AI systems. These enhancements are the first developments from the lab to be integrated into a commercial offering. 

Gilead Sciences, a leading biopharmaceutical company and Cognizant customer, commented on the enhanced Neuro® ^AI  platform: 

“Many companies struggle to apply AI beyond predicting outcomes because solving real business problems typically involves thousands of different scenarios, often with competing priorities,” said Murali Vridhachalam , Head of Cloud, Data and Analytics at Gilead Sciences. “With these latest updates, Cognizant Neuro® AI is ^the  only platform I’m aware of that enables companies to rapidly deploy end-to-end Gen AI use cases across applications and uncover tangible, revenue-generating opportunities. Its innovative, multi-agent approach to managing decision workflows makes it unique in the industry.” 

Another Cognizant customer, Bayer Crop Science, also commented on its experience with the enhanced platform:

“Agriculture is one of the most challenging professions, requiring complex decisions to be made amid environmental uncertainty and the need to balance social, economic and environmental goals,” said Patricio Salvatore La Rosa , Head of Decision Science at Bayer Crop Science. “We directly tested several core components of Cognizant Neuro ^®  AI, especially LEAF, to effectively navigate complex scenarios. By leveraging the collaborative capabilities of specialized Gen AI agents, we look forward to solving complex decision-making challenges in a reliable, transparent and trustworthy way.”

Cognizant has integrated powerful new features as part of its enhancements to Cognizant Neuro ^®  AI. These include Opportunity Finder, a multi-agent-powered discovery tool for mapping use cases, and a suite of large language model (LLM) assistants that form a powerful AI decision engine. Clients are first introduced to the platform through Opportunity Finder, an LLM assistant that helps identify potential AI decision cases for their business. The Model Orchestrator, a drag-and-drop interface, then enables users to clean the data and apply various machine learning models to it. LLMs streamline data preparation, with applied machine learning models predicting outcomes while evolutionary AI models prescribe decisions. Once trained, the best models can be further explored or queried via a web interface or an LLM assistant. 

The enhanced Cognizant Neuro® ^AI  platform is available with prebuilt configurations that provide simple starting points for a variety of use cases. These include healthcare (such as drug discovery and treatment planning), finance (such as cybersecurity and fraud prevention), agriculture (such as crop yield optimization and pesticide development), and general templates for supply chain, call centers, customer engagement, and pricing optimization. 

“Enterprises are struggling with how and where to apply AI to solve business problems, which is why we see most AI use cases limited to prediction-based outcomes or solutions based on a single LLM chat,” said Babak Hodjat , Chief Technology Officer of AI at Cognizant. “Multi-agent AI systems are key to solving these problems, which is why Cognizant Neuro® AI is ^now  built with such a system at its core. This platform puts business leaders – not just data scientists – in the driver’s seat, enabling them to use their own domain knowledge to quickly test and identify AI use cases in minutes, then deliver the resulting model code to iterate at scale.” 

Gartner® states, “Multiple agents can work toward a common goal that exceeds the capabilities of individual agents. The combined application of multiple agents handles complex tasks that individual agents cannot handle, while creating more adaptable, scalable, and robust solutions. ^“ 1

Neil Ward-Dutton , VP Automation, AI, and Analytics at IDC, also commented: “As enterprises take a strategic approach to AI and move beyond experimentation, they are eager to understand how to identify and prioritize use cases. Vendors will be in a strong position if they use technology to identify use cases faster, then use that technology to test and scale deployments.” 

To learn more about the enhanced Cognizant Neuro® ^AI  platform and to register for a demo, visit cognizant.com/neuroai .

Over Cognizant 

Cognizant (Nasdaq: CTSH ) builds modern businesses. We help our clients modernize technology, redesign processes, and transform experiences to stay ahead in our rapidly changing world. Together, we improve everyday life. See how at www.cognizant.com  or @cognizant. 

Over het Cognizant AI Research Lab 

The Cognizant AI Research Lab’s mission is to maximize human potential with Decision AI, a form of AI that combines generative AI, multi-agent architecture, deep learning, and evolutionary AI to create advanced decision-making systems. Decision AI powers Cognizant’s Neuro® ^AI  platform, which is used by Fortune 500 companies and nonprofits to discover new ways to exceed their goals. The platform enables organizations to rapidly build AI to optimize decision-making, driving revenue growth and societal progress.  

Led by AI pioneers Babak Hodjat and Risto Miikkulainen, the lab collaborates with institutions, academia, and technology partners to responsibly develop groundbreaking AI solutions. With more than 75 patents issued or pending, the lab excels at combining scientific innovation with commercial applications. It supports Cognizant’s purpose of improving daily life, with a focus on business and AI-for-good applications. 

Forward-looking statements

This press release contains statements that may constitute forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks, uncertainties and assumptions as to future events that may not prove to be accurate. These statements include, but are not limited to, express or implied forward-looking statements regarding the application of generative artificial intelligence and the effects of generative artificial intelligence on the workforce, business and the economy. These statements are neither promises nor guarantees, but are the findings of the research discussed above and remain subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those described in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Factors that could cause results to differ materially from those expressed or implied include general economic conditions, the impact of technological development and competition, the competitive and rapidly changing nature of the markets in which we operate, the competitive market for talent and its impact on recruiting and retaining employees, and other factors discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

¹  Gartner: Innovation Insight: AI Agents, April 3, 2024 . GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

For more information please contact:

Video – https://mma.prnewswire.com/media/2531529/Cognizant_Neuro_AI_Enhancements_Video.mp4
Logo – https://mma.prnewswire.com/media/1794711/Cognizant_Logo_V1.jpg